Crescent Grove Advisors’s Chemours CC Stock Holding History

Crescent Grove Advisors’s Portfolio CC Stock Details CC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,500	Closed	-$203K	–	280
2023 Q2	$203K	Buy	+5,500	New	+$168K	0.02%	282

Other funds holding CC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Crescent Grove Advisors's CC Position: Q3 2023 in Review

Crescent Grove Advisors sold out of Chemours (CC) in Q3 2023, closing a stake of 5,500 shares — an estimated $203K sold.

Crescent Grove Advisors first reported a position in CC in Q2 2023 and held it in 1 quarter. The position peaked at $203K in Q2 2023. 455 funds tracked by Wall St. Rank hold CC as of Q3 2023.

Crescent Grove Advisors reported no remaining Chemours position as of Q3 2023 after selling out during the quarter.
Crescent Grove Advisors sold 5,500 Chemours shares in Q3 2023, an estimated $203K.
Crescent Grove Advisors first reported a position in Chemours in Q2 2023 and held it in 1 quarter.
Crescent Grove Advisors's Chemours position peaked at $203K in Q2 2023.
455 funds tracked by Wall St. Rank held Chemours as of Q3 2023.

Based on Crescent Grove Advisors's 13F filing for Q3 2023, filed 25 Oct 2023.